Related references
Note: Only part of the references are listed.Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma
Dongrui Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Tuning the Antigen Density Requirement for CAR T-cell Activity
Robbie G. Majzner et al.
CANCER DISCOVERY (2020)
The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status
Wei-jun Chen et al.
CELL DEATH & DISEASE (2020)
Brain immunology and immunotherapy in brain tumours
John H. Sampson et al.
NATURE REVIEWS CANCER (2020)
The blood-brain barrier and blood-tumour barrier in brain tumours and metastases
Costas D. Arvanitis et al.
NATURE REVIEWS CANCER (2020)
Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Sneha Ramakrishna et al.
CLINICAL CANCER RESEARCH (2019)
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies
Bryan D. Choi et al.
CLINICAL CANCER RESEARCH (2019)
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Robbie G. Majzner et al.
CLINICAL CANCER RESEARCH (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Immunotherapy of Primary Brain Tumors: Facts and Hopes
Robin A. Buerki et al.
CLINICAL CANCER RESEARCH (2018)
Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma
Christine E. Brown et al.
MOLECULAR THERAPY (2018)
CART-Cell Therapies in Glioblastoma: A First Look
Denis Migliorini et al.
CLINICAL CANCER RESEARCH (2018)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma
Giedre Krenciute et al.
MOLECULAR THERAPY (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Christine E. Brown et al.
CLINICAL CANCER RESEARCH (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
Laura A. Johnson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma
Yi Liu-Chittenden et al.
CANCER MEDICINE (2015)
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy
Bart Thaci et al.
NEURO-ONCOLOGY (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Epidermal Growth Factor Receptor Inhibition in Lung Cancer Status 2012
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Glioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis
Christine E. Brown et al.
PLOS ONE (2013)
Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2
Chuan Hua He et al.
CELL REPORTS (2013)
Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor-Modified T Cells
Seogkyoung Kong et al.
CLINICAL CANCER RESEARCH (2012)
Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine-Redirected T Cells
Christine E. Brown et al.
CLINICAL CANCER RESEARCH (2012)
Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele
Kenichiro Iwami et al.
CYTOTHERAPY (2012)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Chemokines and Chemokine Receptors: Standing at the Crossroads of Immunobiology and Neurobiology
Richard M. Ransohoff
IMMUNITY (2009)
Expression of interleukin-13 receptor α2 in glioblastoma multiforme:: Implications for targeted therapies
John S. Jarboe et al.
CANCER RESEARCH (2007)
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group
Sandeep Kunwar et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Primary brain tumors treated with steroids and radiotherapy: Low CD4 counts and risk of infection
MA Hughes et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Analysis of interleukin-13 receptor α2 expression in human pediatric brain tumors
M Kawakami et al.
CANCER (2004)
IL-13 receptors and signaling pathways: An evolving web
GKK Hershey
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)
IL-13Rα2 is a glioma-restricted receptor for interleukin-13
A Mintz et al.
NEOPLASIA (2002)
Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients:: Preliminary study
T Crombet et al.
HYBRIDOMA (2001)
Expression of a restrictive receptor for interleukin 13 is associated with glial transformation
W Debinski et al.
JOURNAL OF NEURO-ONCOLOGY (2000)